The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma

被引:3
|
作者
Xiang, Xiaoyong [1 ,2 ]
Chen, Peng [1 ,2 ]
Lan, Fengming [1 ,2 ]
Ma, Li [1 ,2 ]
Jin, Jing [1 ,2 ,3 ]
Zhang, Ye [3 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp & Shenzhen Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Shenzhen, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,Dept Radiat Oncol, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
nasopharyngeal carcinoma; locoregionally advanced; induction chemotherapy; short-term efficacy; PD-1; GROWTH-FACTOR RECEPTOR; CHEMORADIOTHERAPY; MULTICENTER; RADIOTHERAPY; GEMCITABINE; EXPRESSION; PLACEBO; PHASE-3; NPC;
D O I
10.3389/fonc.2023.1110281
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThis study aimed to investigate the short-term efficacy and safety of induction chemotherapy (IC) combined with PD-1 inhibitor or anti-EGFR in the treatment of locoregionally advanced nasopharyngeal carcinoma (LA-NPC). Methods and materialsWe retrospectively reviewed the clinical data of 206 patients with LA-NPC, including IC combined with anti-PD-1 (57 patients), IC combined with anti-EGFR (28 patients), and IC alone (121 patients). The short-term efficacy was assessed at the end of IC and one month after overall treatment. According to the RECIST v1.1, the short-term efficacy of cervical lymph nodes and primary nasopharynx foci was divided into complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). The overall response (ORR) was defined as the sum of CR and PR. Acute toxicities were graded according to the CTCAE v5.0. One-way analysis of variance (ANOVA) was used to compare differences in the numerical variables among groups. Fisher Freeman-Halton test or Pearson Chi-square test was used to compare classified variables. ResultsThe ORR rates of primary nasopharynx foci in IC, anti-EGFR, and anti-PD-1 group were 68.60%, 67.9%, and 94.7%, respectively, and the corresponding rates of ORR in cervical lymph nodes were 78.5%, 71.4%, and 93.0%, respectively. There was a statistical difference in the ORR between the three groups. Further analysis showed that after IC or overall treatment, the CR rate of primary nasopharynx foci in the anti-PD-1 group was significantly higher than the other two groups. The most common adverse effects were hematotoxicity, gastrointestinal toxicity, and transaminase elevation. However, there were no statistical differences in the frequency of any common adverse effects between the three groups. ConclusionsThe addition of anti-PD-1 based on IC significantly improved the short-term efficacy of LA-NPC and toxicities were tolerable.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma
    Liu, Qing-Qing
    Wang, Xiang-Xu
    Ji, Hongchen
    Dou, Qiong-Yi
    Zhang, Hong-Mei
    MEDICAL ONCOLOGY, 2024, 41 (05)
  • [42] Efficacy and safety of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitor versus chemotherapy for advanced lung cancer A meta-analysis
    Zhang, Pei-Pei
    Wang, Juan
    Ding, Da-Zhi
    Zhang, Li
    Cheng, Chun
    Chen, Da-Ke
    MEDICINE, 2021, 100 (35) : E27121
  • [43] Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis
    Tang, Si-Qi
    Xu, Cheng
    Wang, Xiao-Shuai
    Tang, Ling-Long
    Li, Wen-Fei
    Chen, Lei
    Mao, Yan-Ping
    Guo, Rui
    Liu, Qing
    Sun, Ying
    Ma, Jun
    ORAL ONCOLOGY, 2020, 105
  • [44] Comparison of the pre-treatment functional MRI metrics' efficacy in predicting Locoregionally advanced nasopharyngeal carcinoma response to induction chemotherapy
    Zhao, Da-wei
    Fan, Wen-jun
    Meng, Ling-ling
    Luo, Yan-rong
    Wei, Jian
    Liu, Kun
    Liu, Gang
    Li, Jin-feng
    Zang, Xiao
    Li, Meng
    Zhang, Xin-xin
    Ma, Lin
    CANCER IMAGING, 2021, 21 (01)
  • [45] Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
    Zhu, Chengpei
    Xue, Jingnan
    Wang, Yunchao
    Wang, Shanshan
    Zhang, Nan
    Wang, Yanyu
    Zhang, Longhao
    Yang, Xu
    Long, Junyu
    Yang, Xiaobo
    Sang, Xinting
    Zhao, Haitao
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [46] Safety and efficacy analysis of PD-1 inhibitors in combination with chemotherapy for advanced pancreatic cancer
    Song, Dong
    Yang, Xuejing
    Guo, Xin
    Sun, Hu
    IMMUNOTHERAPY, 2022, 14 (16) : 1307 - 1313
  • [47] Efficacy and safety of camrelizumab (a PD-1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non-small cell lung cancer
    Hou, Xinlei
    Shi, Xueliang
    Luo, Jie
    ONCOLOGY LETTERS, 2022, 24 (01)
  • [48] Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis
    Liu, Bo-Wei
    Shang, Qi-Xing
    Yang, Yu-Shang
    Chen, Long-Qi
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [49] The efficacy and safety of PD-1 inhibitors combined with chemotherapy treatment for advanced esophageal cancer: a network meta-analysis
    Tian, Jian-Zhou
    Zhang, Li
    Lin, Fu-Yong
    He, Ren-Jiao
    Tian, Wen-Rong
    Yan, Liu
    Huang, Guo-Xin
    Ai, Jin-Wei
    Pei, Bin
    Li, De-Sheng
    FRONTIERS IN MEDICINE, 2025, 11
  • [50] Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
    Wehrenberg-Klee, Eric
    Goyal, Lipika
    Dugan, Matthew
    Zhu, Andrew X.
    Ganguli, Suvranu
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2018, 41 (11) : 1799 - 1802